Cancer Research Fund Request For Applications

Submission timeline: May 5, 2021 (open) - June 16, 2021 (deadline)

Eligible sites: Columbia University Irving Medical Center; Weill Cornell Medicine; Duke University; European Molecular Biology Laboratory; Fred Hutchinson Cancer Research Center; Harvard University (Dana-Farber/Harvard Cancer Center members only); Johns Hopkins University; MD Anderson Cancer Center; Massachusetts Institute of Technology; Memorial Sloan Kettering Cancer Center; University of Oxford; University of California, San Francisco; University of Pennsylvania; Stanford University; Washington University, St. Louis; Weizmann Institute of Science; Yale University

The Emerson Collective Cancer Research Fund is requesting individual or team proposals for research projects related to the following topic areas:

- Engineering allogeneic cells with new properties to:
  - prevent their recognition by the host immune system;
  - promote their persistence in the host;
  - defeat suppressive mechanisms of the tumor microenvironment;
  - synergize with host innate and adaptive immune systems; and/or,
  - allow gating or other regulation of their functions temporally or geographically to improve potency or reduce toxicity.

- Validating new target antigens for cell therapy in cancer

- Targeted intracellular gene or protein delivery mechanisms

- Enabling early cancer detection

Positive criteria include the potential of a project to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer.

We encourage submission of 'high risk/high reward' initiatives.

This RFA is open to all faculty and trainees sponsored by faculty undertaking research relevant to cancer at the above eligible sites. Awards range from 1 to 2 years, $50,000 minimum to $400,000 maximum, which must include both direct and indirect costs. Emerson Collective and associates will evaluate applications on the following positive criteria:

- The audacity and innovation of the research proposal
- The potential of the proposed research to affect multiple cancer types
- The potential to translate said research into further experiments, and clinical trials
- The applicant’s lack of resources to pursue the proposed research
- Compliance with a two-year maximum timeframe for research

Please note: The applicant’s prior experimental track record will not be the principal determining factor in evaluation. This fund does not support incremental research. Emerson Collective evaluates the applicant’s current and pending support. Duplication of proposed science is grounds for Emerson Collective to return the proposal without review.

Apply now. Click here to learn more and to access our submission portal.

Submission portal website:
https://echealthgrants.smapply.io/prog/emerson_collective_cancer_research_fund/

Questions about submitting in Survey Monkey Apply? Please contact healthgrants@emersoncollective.com